DHA Supplementation in Patients With STGD3

Not Applicable

Completed

• Conditions: Dominantly Inherited Stargardt's Disease (STGD3)
• Interventions: Dietary Supplement: Over the counter DHA/EPA dietary supplementation

• Registration Number: NCT00420602
• Lead Sponsor: University of Utah

Brief Summary

We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients. Therefore, the purpose of this study is to follow STGD3 patients as they supplement their diets with DHA/EPA.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2007-01-10
• Study First Submitted QC: 2007-01-10
• Study First Posted: 2007-01-11
• Study Start: 2007-09-21
• Primary Completion: 2017-12-27
• Study Completion: 2017-12-27
• Status Verified: 2018-05
• Last Update Submitted: 2018-05-08
• Last Update Posted: 2018-05-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• All Moran Eye Center patients with STGD3

Exclusion Criteria

• All others

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single Arm, Open Label	Over the counter DHA/EPA dietary supplementation	Single Arm, Open Label

Primary Outcome Measures

Name	Time	Method
ERG	1 year

Secondary Outcome Measures

Name	Time	Method
Visual acuity	1 year

Trial Locations

Locations (1)

Moran Eye Center, University of Utah; 🇺🇸 Salt Lake City, Utah, United States